None
Quote | Vaccinex Inc. (NASDAQ:VCNX)
Last: | $6.72 |
---|---|
Change Percent: | -2.17% |
Open: | $7.05 |
Close: | $6.72 |
High: | $7.1 |
Low: | $6.63 |
Volume: | 63,010 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Vaccinex Inc. (NASDAQ:VCNX)
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Message Board Posts | Vaccinex Inc. (NASDAQ:VCNX)
Subject | By | Source | When |
---|---|---|---|
Taking a dip lower premarket | harry crumb | investorshub | 02/08/2023 12:52:46 PM |
Need more volumn | harry crumb | investorshub | 02/07/2023 3:52:50 PM |
5@ 100% runs in past, patent news should | 81vette | investorshub | 02/07/2023 3:41:37 PM |
near bottom here MAs curving up,looking for dbl | 81vette | investorshub | 02/07/2023 3:13:00 PM |
258Xs ave vol,big $ buying,institutions like patent news | 81vette | investorshub | 02/07/2023 3:05:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...